Industry
Biotechnology
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
March 12, 2024 | 10:36 am
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
February 16, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Insights
February 13, 2024 | 1:06 pm
Portfolio Pulse from Benzinga Newsdesk
January 17, 2024 | 11:03 am
Portfolio Pulse from Benzinga Newsdesk
December 21, 2023 | 11:04 pm
Portfolio Pulse from Benzinga Newsdesk
December 06, 2023 | 11:02 pm
Portfolio Pulse from Benzinga Newsdesk
November 20, 2023 | 3:08 pm
Portfolio Pulse from Benzinga Insights
November 20, 2023 | 1:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.